ESLA
Estrella·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ESLA
Estrella Immunopharma, Inc.
A preclinical-stage biopharmaceutical company developing T-cell therapies
Biological Technology
01/06/2021
09/14/2021
NASDAQ Stock Exchange
3
12-31
Common stock
5858 Horton Street, Suite 370, Emeryville, California, 95608
--
Estrella Immunopharma, Inc., was incorporated in Delaware on January 6, 2021. The Company is a preclinical stage biopharmaceutical company developing CD19 and CD22 targeted ARTEMIS T cell therapies with the ability to address the therapeutic challenges of patients with blood cancer and solid tumors. The company's mission is to harness the evolutionary power of the human immune system to transform the lives of cancer patients. To accomplish this mission, the company's lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The company is also developing EB104, which also utilizes Eureka's ARTEMIS technology, not only for CD19, but also for CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies.
Company Financials
EPS
ESLA has released its 2025 Q2 earnings. EPS was reported at -0.15, versus the expected -0.11, missing expectations. The chart below visualizes how ESLA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
